scholarly journals Influence of dupilumab on the economic burden of severe asthma and atopic dermatitis

2020 ◽  
pp. 15-26
Author(s):  
I. S. Krysanov ◽  
V. S. Krysanova ◽  
O. I. Karpov ◽  
V. Yu. Ermakova
Keyword(s):  
Atopic Dermatitis ◽  
Severe Asthma ◽  
Economic Burden ◽  
Weighted Average ◽  
Indirect Costs ◽  
Current Treatment ◽  
Severe Atopic Dermatitis ◽  
Local Conditions ◽  
Economic Burden Of Disease

The prevalence of comorbidity — asthma and atopic dermatitis — is not understood well yet. More severe processes decreasing quality of life and increasing a social-economic burden of disease are occurred in such kind comorbidity.Aim: an evaluation of economic burden of non-control severe asthma in combination with severe atopic dermatitis in the local conditions.Materials and methods. Analysis has been performed for adult patients; the bottom-up approach of costs evaluation was used. Direct medical and non-medical as well as indirect costs were calculated for two models: Model 1 — current practice of the treatment, Model 2 — treatment with Dupilumab. Results. Model 1 — Weighted average expenditures for one patient were 3,1 mln RUR, indirect costs were dominated (76 % from the total), severe atopic dermatitis had 15 % of total. Model 2 (with Dupilumab) — Dupilumab has decreased the total weighted average cost on 903 905 RUR. The total economic burden of comorbidity was 17,6 bln RUR in the current treatment option, and 12,4 bln RUR in Dupilumab hand (different is 5,2 bln RUR, or burden decrease is expected on 29,2 %).Conclusion. The wider introduction of Dupilumab into clinical practice, which allows achieving control in the treatment of severe asthma and severe atopic dermatitis, should reduce treatment costs and reduce the socio-economic burden of these diseases as a result.

scholarly journals Impact of subcutaneous specific-allergen immunotherapy in the quality of life of brazilian moderate/severe atopic dermatitis patients

2015 ◽  
Vol 8 ◽  
pp. A74
Author(s):  
Ana Julia Teixeira ◽  
Luciana Kase Tanno ◽  
Luciana Kase Tanno ◽  
Romero Kopke ◽  
Cintia Bassani ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Atopic Dermatitis ◽  
Allergen Immunotherapy ◽  
Severe Atopic Dermatitis ◽  
Specific Allergen

A social-economic burden of rhinosinusitis with nasal polyps with comorbid asthma and influence of dupilumab

2021 ◽  
pp. 16-30
Author(s):  
I. S. Krysanov ◽  
V. S. Krysanova ◽  
V. Yu. Ermakova
Keyword(s):  
Medical Cost ◽  
Economic Burden ◽  
Nasal Polyps ◽  
Social Economic ◽  
Weighted Average ◽  
Indirect Costs ◽  
Biologic Drugs ◽  
State Position ◽  
The Russian Federation ◽  
Regions Of Russia

Rhinosinusitis with nasal polyps (RwNP) is a one of most common comorbidities in asthma and contrariwise and can lead to exacerbation of severe asthma (SA). Dupilumab is a perspective medicine for treatment of both, because it decreases exacerbations and prevents of a necessity of surgeon. Economics aspects of dupilumab treatment in RwNP + SA are not examined yet. Thus aim of this study was evaluation of social-economic burden of RwNP + SA in the Russian Federation and dupilumab influence on it. Materials and methods. Direct medical (cost of medicines, treatment in outpatients department and in hospital, including surgery and rate of exacerbations per year) and non-medical (payment for temporary and stable disability) and indirect costs (GDP loses) in RwNP + SA patients have been evaluated. Medical cure of a patient with RwNP + SA was created according to survey of experts from different regions of Russia. Modelling of expenditures was prepared on all calculated cohort of potential patients with RwNP + SA from “State” position and growing approach. Results. Expenditures for cure of one patient with RwNP were as 234 217,71 RUR/year. Weighted average costs for one patient with RwNP + SA were 1 881 883,39 RUR, and mostly were associated with indirect costs. Dupilumab can decrease expenditures for one patient with RwNP + SA till 1 593 162,87 RUR (on 15,3 %) annually. Potential cohort with RwNP + SA has been estimated above 39 thousand patients. Total economic burden of RwNP + SA in Russia were estimated as 1,7 bln RUR. Dupilumab usage in patients with RwNP + SA fixed in Register can help decrease economic burden on 259 mln RUR annually. Hidden economic burden of comorbidity can reach 73,4 bln RUR (for all calculated / modelled cohort of patients with RwNP + SA), dupilumab saves 11,3 bln RUR annually in this scenario. Conclusion. Comorbid pathology — RwNP+SA has a sufficient social-economic burden in Russia, that could be decreased by modern biologic drugs, in particular, with dupilumab.

scholarly journals Economic Burden of Adult Patients with Moderate to Severe Atopic Dermatitis Indicated for Systemic Treatment

2019 ◽  
Vol 99 (9) ◽  
pp. 762-768 ◽  
Author(s):  
L Ariëns ◽  
K Nimwegen ◽  
M Shams ◽  
D Bruin ◽  
J Schaft ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Economic Burden ◽  
Systemic Treatment ◽  
Adult Patients ◽  
Severe Atopic Dermatitis

scholarly journals Clinical Response and Quality of Life in Patients with Severe Atopic Dermatitis Treated with Dupilumab: A Single-Center Real-Life Experience

2020 ◽  
Vol 9 (3) ◽  
pp. 791 ◽  
Author(s):  
Silvia Ferrucci ◽  
Giovanni Casazza ◽  
Luisa Angileri ◽  
Simona Tavecchio ◽  
Francesca Germiniasi ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Atopic Dermatitis ◽  
Rating Scale ◽  
Real Life ◽  
Life Quality ◽  
Depression Scale ◽  
Interleukin 4 ◽  
Severe Atopic Dermatitis ◽  
Single Center

Dupilumab is an anti-interleukin-4 receptor monoclonal antibody that was recently approved for the treatment of atopic dermatitis (AD). In this single-center retrospective study, clinical baseline data of 117 severe AD patients treated with dupilumab were collected. At baseline and at weeks 4 and 16, disease severity was assessed through the Eczema Area and Severity Index (EASI) and quality of life through the Dermatology Life Quality Index (DLQI) questionnaire, Patient-Oriented Eczema Measure (POEM), Hospital Anxiety and Depression Scale (HADS), Peak Pruritus Numerical Rating Scale (NRS-itch), and VAS-sleep. Response to dupilumab was defined as an improvement of ≥75% in EASI from baseline (EASI75). At multivariate analysis, AD onset before 18 years [OR, 2.9; 95% CI, 1.2–7.2; p = 0.0207] and absence of hypereosinophilia [OR, 2.24; 95% CI, 1.03–4.86; p = 0.0412] were identified as significant predictive parameters for response to dupilumab in terms of EASI75 at week 4 but not at week 16. Significant reductions in EASI, DLQI, POEM, HADS, NRS-itch, and VAS-sleep were found between week 4 versus baseline (p < 0.0001 for all) and week 16 versus baseline (p < 0.0001 for all). Early AD onset and absence of hypereosinophilia may be suggested as predictive markers of early response to dupilumab. We confirmed the efficacy and safety of this agent along with the improvement of life quality in severe AD patients.

scholarly journals Patient Reported Outcome Measure in Atopic Dermatitis Patients Treated with Dupilumab: 52-Weeks Results

2021 ◽  
Author(s):  
Servando E. Marron ◽  
Lucia Tomas-Aragones ◽  
Carlos A. Moncin-Torres ◽  
Manuel Gomez-Barrera ◽  
Francisco Javier Garcia-Latasa de Aranibar
Keyword(s):  
Quality Of Life ◽  
Atopic Dermatitis ◽  
Clinical Practice ◽  
Stressful Life Events ◽  
Severe Disease ◽  
Patient Reported Outcome ◽  
Routine Clinical Practice ◽  
Severe Atopic Dermatitis ◽  
Patient Reported

Dupilumab is used to treat atopic dermatitis patients who have proven to be refractory to previous treatments. The aim of this study was to assess evolution and patient reported outcome measures in adult patients with moderate-to-severe atopic dermatitis treated with Dupilumab in routine clinical practice. The outcomes were evaluated and registered at baseline and weeks-16, 40 and 52. The variables evaluated were: diseases severity, pruritus, stressful life events, difficulty to sleep, anxiety and depression, quality of life, satisfaction, adherence to the treatment, efficacy and safety. Eleven patients were recruited between Nov 14th 2017 and Jan 16th 2018. Demographic variables: 90% Caucasian, 82% women. Clinical variables: Mean duration of AD =17.7 (&plusmn;12.8), 91% had severe disease severity. At baseline, SCORAD mean score = 61.7 (&plusmn;15.5); itch was reported by 100% of patients; itch Visual Analogue Scale mean range of 8 (6-10); HADS mean total score =13.9 (&plusmn;5.5); DLQI mean score =13.3 (&plusmn;8.3): EQ-5D-3L mean range = 57 (30-99). At week-52 there is a significant reduction of SCORAD scores, HADS total score and improved quality of life. &iexcl;This study confirms that Dupilumab, used for 52-weeks under routine clinical practice, maintains the improved atopic dermatitis signs and symptoms obtained at week-16, with a good safety profile.

scholarly journals Economic Burden of Osteoporosis in the World: A Systematic Review

2020 ◽  
Author(s):  
Asma Rashki kemmak ◽  
Aziz Rezapour ◽  
Reza Jahangiri ◽  
Shima Nikjoo ◽  
Hiro Farabi ◽  
...  
Keyword(s):  
Economic Burden ◽  
Research Question ◽  
Methodological Approach ◽  
Indirect Costs ◽  
Osteoporotic Fractures ◽  
Health Care Planning ◽  
Skeletal Disease ◽  
Increased Risk ◽  
The World

Abstract Background Osteoporosis is a skeletal disease that is associated with a reduction in bone mass and microstructures and deterioration of bone tissue. It is also associated with an increased risk of fracture that is the most important complication of osteoporosis. Osteoporosis and consequent fractures not only have a major impact on the health and quality of life, but also impose a significant economic burden on the health system of countries. Objective Since the population of many countries around the world is aging, the incidence of fractures due to osteoporosis is increasing too. The knowledge about costs and economic aspects of osteoporosis plays an important role in making policies and planning measures for the prevention and management of this disease, hence, this study systematically investigated the available evidence on the costs associated with osteoporosis worldwide. Methods Considering language, year of publication, and the research question, electronic searches were conducted in multiple databases and different sources. After selecting articles based on inclusion and exclusion criteria, the data were extracted and the results were summarized. To prevent bias, the whole procedure was performed by three researchers. Results Of a total of 1989 papers, 28 papers were included in the study on the basis of inclusion criteria. Among the selected studies, 13 papers reported direct and indirect costs. Based on the data extracted from the mentioned studies, the mean age of people with osteoporotic fractures was 50 years, with the highest costs associated with hip fractures. Conclusion There is a paucity of studies investigating the burden of osteoporosis in the world. The available studies indicate a lack of standardization in the methodological approach of assessing the economic burden of this disease. It is necessary to highlight the importance of studies on osteoporosis to inform policymakers and enhance health care planning.

Sign in / Sign up

Export Citation Format

Share Document